Contact

Crown Bio Signals Increased Investment in Digital Transformation with Appointment of New COO

San Diego, Calif - August, 6 2020 - Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.

Topics: Corporate

New NAFLD/NASH Preclinical Model Data to be Presented at ADA 2020

San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.

Topics: RR & IVD

MBL has concluded the license agreement regarding fully human monoclonal antibodies for four (4) infectious diseases.

NAGOYA, Japan - May 11, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announces today that MBL has concluded the license agreement with China National Biotec Group Co., Ltd. (CNBG) of a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) to comprehensively license fully human monoclonal antibodies generated by MBL for four (4) infectious diseases treatment. Under this license agreement, MBL confirms the development plan implemented by CNBG and its progress, and receives a license fee including running royalties as consideration for this license. CNBG
acquires the exclusive license to develop, manufacture, and sell those antibodies and to use related technical know-hows in China and the other Asian regions (excluding Japan), and begin development in China.

The fully human monoclonal antibodies were generated by using MBL’s basic technology of the
SPYMEG* or the phage display technology. The antibodies are expected to help in treating and
preventing pandemic infections including Influenza because of their broadly neutralizing activity.

MBL Launches New ELISA-based Companion Diagnostic Kit for Spinal Muscular Atrophy

NAGOYA, Japan - May 8, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that it has launched an in vitro diagnostic kit for the genetic disease Spinal Muscular Atrophy (SMA). The MEBCDX AAV9 test kit, which was licensed from Quest Diagnostics, was approved on April 27 by the Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic (CDx) kit for the SMA gene therapy ZolgensmaTM (onasemnogene abeparvovec-xioi) launched by Novartis International AG. The test kit will enable laboratory testing through LSI Medience Corporation starting today. 

Topics: RR & IVD

CrownBio Announces C-Suite Leadership Changes

San Diego, CA - April 14, 2020 - Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC.

Topics: Corporate

Medical & Biological Laboratories Co., Ltd. launches real time PCR-based assay kit products for SARS-CoV-2

NAGOYA, Japan - March 23, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that its subsidiary company, G&G Science Co., Ltd., has successfully completed development of a real-time PCR assay kit for “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The kit was evaluated with clinical samples provided by the National Institute of Infectious Diseases (NIID). NIID and the Japan Ministry of Health, Labour and Welfare (MHLW) today published that the results of testing with the kit corresponded 100 percent to those of the current NIID system on both positive and negative agreement rates. Therefore, starting immediately, the kit can be used not only for emergency testing being executed under the Infectious Diseases Control Law of Japan, but also for the clinical testing for the coverage of public medical insurance.

Topics: RR & IVD

Featured